Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-23-028 from the NIH Guide for Grants and Contracts. The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents. (Source: NIH Funding Opportuniti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 23, 2023 Category: Research Source Type: funding
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-139 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 22, 2023 Category: Research Source Type: funding
Centers for Oceans and Human Health 4: Impacts of Climate Change on Oceans and Great Lakes (COHH4) (P01 Clinal Trial Optional)
Funding Opportunity RFA-ES-22-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for multi-component projects that will investigate the impact of climate change on emerging public health threats associated with marine and Great Lakes Basin environments. The focus of the program will be to support research on the exposures, toxicities and human health impacts that arise in these environments and how climate change is influencing these factors now and in the future. The FOA solicits applications that will achieve program goals through integ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 31, 2022 Category: Research Source Type: funding
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this FOA are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and pote...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 26, 2022 Category: Research Source Type: funding
Online Self-Paced Learning: Farm Toxicology for Primary Care - Recognition and Management of Pesticide Poisoning
An online self-paced course that focuses on the recognition and management of pesticide poisonings in primary care, including the long-term consequences of pesticide exposure. Geographic coverage: Nationwide -- Eastern AHEC (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - August 25, 2022 Category: American Health Source Type: funding
Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (DILIN) (U01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-22-508 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement is a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and build a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in Herbal and Dietary Supplements (HDS) implicated in liver toxicity. This RFA and companion [RFA-D...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2022 Category: Research Source Type: funding
Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-23-056 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the effects of an overdose and the observed toxicities caused by acute Ultra-Potent Synthetic (UPS) opioid exposure. This FOA will also support mechanistic studies of persistent or delayed pathophysiological effects after acute exposure to UPS opioids. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 17, 2022 Category: Research Source Type: funding
Cellular and Molecular Mechanisms of Prion-Like Aggregate Seeding, Propagation, and Neurotoxicity in AD/ADRD (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-023 from the NIH Guide for Grants and Contracts. The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious va...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 25, 2022 Category: Research Source Type: funding
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Funding Opportunity PAR-22-216 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical tr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 14, 2022 Category: Research Source Type: funding
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-209 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 6, 2022 Category: Research Source Type: funding
New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-22-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically rel...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 30, 2022 Category: Research Source Type: funding
Request for Proposals FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms to Support Novel Tissue Imaging, Remote Sensing, and Toxicity Challenges
Notice NOT-CA-22-028 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 22, 2021 Category: Research Source Type: funding
Notice of NIEHS Participation on PAR-22-048 "Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)"
Notice NOT-ES-22-002 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 19, 2021 Category: Research Source Type: funding
Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-048 from the NIH Guide for Grants and Contracts. There is consensus that environmental toxicants are a risk factor for AD/ADRD, but causality has been largely elusive. While human studies demonstrating an association of AD/ADRD with toxicant exposures are relatively abundant, there is a clear unmet need for more mechanistic research to support or refute the clinical relevance and the biological plausibility of an impact on disease initiation, progression, or modification. This is especially important for understanding the potentially modifiable causes of racial and socioeconomic inequities. Th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2021 Category: Research Source Type: funding
Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)
Funding Opportunity RFA-DA-22-022 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research to understand and respond to new challenges in the treatment of drug addiction and overdose, introduced by the now widespread presence of fentanyl and its analogs (fentanils) in illicit drug supplies. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 12, 2021 Category: Research Source Type: funding
